Northland Capital issued a report on Motif Bio Plc (LON:MTFB), maintaining its target price at 140.00GBX today
- Updated: September 18, 2016
Northland Capital held the target price of Motif Bio Plc (LON:MTFB) at 140GBX, reporting a possible upside of 0.00%.
Previously on 8/09/2016, Northland Capital released a statement for Motif Bio Plc(LON:MTFB) bumped the target price at 140.00GBX. At the time, this suggested an upside of 1.71%.
Only yesterday Motif Bio Plc (LON:MTFB) traded 2.00% higher at 0.00GBX. The company’s 50-day moving average is 51.29GBX and its two hundred day average is 47.18GBX. The last stock price close is down 8.09% from the 200-day average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same time. 95,888 shares of the stock were exchanged, down from ann average volume of 265,673.
Recent Performance Graph:
Motif Bio Plc has a 52 week low of 35.50GBX and a 52 week high of 68.25GBX and has a market cap of 0.0 GBX.
In addition to Northland Capital reporting it’s price target, a total of 1 broker has issued a research note on the stock. The 12-month target price is 114.00GBX with one analyst rating the company a strong buy, 0 rating the company a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 firmsrating the stock as sell.
Brief Synopsis About Motif Bio Plc (LON:MTFB)
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and and is pursuing programs in various stages of development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.